Longevity & Anti-Aging

NNMT Inhibitor. Small molecule NNMT (nicotinamide N-methyltransferase) inhibitor. Blocks NNMT to elevate NAD+ and SAM, improve mitochondrial function, and reduce fat cell activity. Metabolic health, fat loss, NAD+ elevation.

T2D medication with longevity properties. ITP study showed 20% lifespan extension in male mice. Modulates gut microbiome, increases GLP-1, reduces glycemic variability. Brand names: Precose, Glucobay.

Novel mitochondrial protonophore uncoupler. Reverses diet-induced obesity in mice without affecting food intake or lean mass. More potent and selective than DNP.

At low doses (1.5-4.5mg), intermittently blocks opioid receptors causing upregulation. Anti-inflammatory, immune modulating, neuroprotective. Off-label for autoimmune, fibromyalgia, cancer.

First-line T2D medication with compelling anti-aging data. Activates AMPK, inhibits mTOR and Complex I. TAME trial ongoing for aging indication. Brand names: Glucophage, Glumetza.

NAD+ precursor that converts to NMN then NAD+. Clinically shown to increase NAD+ levels by ~60% in humans. Reduces arterial stiffness, neuroprotective. Brand name: Tru Niagen.

Direct NAD+ precursor. Elevates cellular NAD+ more efficiently than NR in some studies. Activates sirtuins. Declines with age.

NAD+ precursor that converts to NMN then NAD+. Clinically shown to increase NAD+ levels by ~60% in humans. Reduces arterial stiffness, neuroprotective. Brand name: Tru Niagen.

Most potent known longevity drug. Inhibits mTORC1 to suppress cellular senescence. Consistently extends lifespan in animals. Used off-label in small longevity doses. Brand name: Rapamune.

Orally bioavailable REV-ERB agonist. Regulates circadian rhythm, metabolic function, fat oxidation, and muscle endurance. Studied as exercise mimetic.

Triple monoamine reuptake inhibitor (SNDRI). Originally developed for Parkinsons/Alzheimers. Significant appetite suppression and weight loss in trials (10.6% weight loss at 0.5mg/day).